The major fraction of oncogenic NF-κB activating mutations in DLBCL is predominantly related to the canonical NF-κB pathway [12, 16, 18, 19, 96, 104, 259]. This evidence concerns the gene NFKB1 and diffuse large B-cell lymphoma.